How Heart Devices Sometimes Struggle and What New Treatments Could Do

Some people with heart failure get a special device called a cardiac resynchronization therapy (CRT) implant. This gadget sends electrical signals to help the heart beat in sync. But for nearly half of patients, it just doesn’t work well. When that happens, their heart function stays poor, and they’re more likely to end up in the hospital. Doctors call this a case of CRT nonresponse—a big problem because it means the treatment failed its primary job. Researchers looked into why some hearts don’t respond to CRT and found a surprising clue in the tiny powerhouses of cells: mitochondria. These are like the batteries inside heart muscle cells. When they don’t work right, the heart weakens further. A new drug called vericiguat steps in to help these mitochondria by boosting a natural chemical signal. Early studies show it might improve how well the heart works in people who didn’t benefit from their CRT device.This isn’t just about one pill fixing everything. It’s about understanding that when standard treatments fall short, other parts of the body’s chemistry could hold the answer. The heart doesn’t just beat—it relies on complex energy systems that can break down under strain. So, instead of seeing CRT failure as a dead end, scientists are exploring how fixing the heart’s energy supply could lead to better health outcomes. Still, not everyone agrees on how much vericiguat can help. Big trials are still needed. Some experts think the real issue isn’t just the mitochondria—it’s also how the heart’s structure changes over time. Others worry that adding another drug might complicate care without solving the root problem. The debate shows how tricky heart disease can be.